This suggests that some of the novel signatures identified in this analysis could also serve as potential biomarkers for the different cancer types, for example: Galectin-7 (encoded by the genes LGALS7, LGALS7B) for squamous cell carcinomas; MUC21 for lung adenocarcinomas, ST3GAL4 for melanomas, MUCL1 for breast cancer (No TNBC), FUT9 for brain cancers, and FUT7 for leukemia (Figure 1C). Here, MUCL1 is linked to breast carcinoma.